CA2465862A1 - Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism - Google Patents

Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism Download PDF

Info

Publication number
CA2465862A1
CA2465862A1 CA002465862A CA2465862A CA2465862A1 CA 2465862 A1 CA2465862 A1 CA 2465862A1 CA 002465862 A CA002465862 A CA 002465862A CA 2465862 A CA2465862 A CA 2465862A CA 2465862 A1 CA2465862 A1 CA 2465862A1
Authority
CA
Canada
Prior art keywords
pth
level
agonist
antagonist
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465862A
Other languages
English (en)
French (fr)
Inventor
Thomas L. Cantor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scantibodies Laboratory Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/002,818 external-priority patent/US6524788B1/en
Application filed by Individual filed Critical Individual
Publication of CA2465862A1 publication Critical patent/CA2465862A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002465862A 2001-11-02 2002-11-04 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism Abandoned CA2465862A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/002,818 US6524788B1 (en) 2001-11-02 2001-11-02 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US10/002,818 2001-11-02
US10/286,465 US7056655B2 (en) 2001-11-02 2002-11-01 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US10/286,465 2002-11-01
PCT/US2002/035516 WO2003039572A1 (en) 2001-11-02 2002-11-04 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism

Publications (1)

Publication Number Publication Date
CA2465862A1 true CA2465862A1 (en) 2003-05-15

Family

ID=26670921

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465862A Abandoned CA2465862A1 (en) 2001-11-02 2002-11-04 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism

Country Status (5)

Country Link
US (2) US7056655B2 (https=)
EP (1) EP1448217A4 (https=)
JP (1) JP2005513419A (https=)
CA (1) CA2465862A1 (https=)
WO (1) WO2003039572A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6838264B2 (en) * 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
WO2007047327A2 (en) * 2005-10-12 2007-04-26 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
HUE037309T2 (hu) * 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
PT3335712T (pt) 2007-04-25 2025-10-23 Opko Renal Llc Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
US8592401B2 (en) 2007-04-25 2013-11-26 Proventiv Therapeutics, Llc Methods and compounds for vitamin D therapy
PL2148661T3 (pl) 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
CN108445237A (zh) * 2018-06-20 2018-08-24 广州市康润生物科技有限公司 一种pth快速免疫检测系统的新用途
CN112349362B (zh) * 2019-08-08 2025-06-20 深圳先进技术研究院 一种甲状旁腺激素分泌监测与调控系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369138A (en) 1980-07-15 1983-01-18 Immuno Nuclear Corporation Parathyroid radioimmunoassay
US4423037A (en) 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4508828A (en) 1983-03-21 1985-04-02 Immuno Nuclear Corporation Bioassay of parathyroid hormone
FR2550204B1 (fr) 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
DE3347548A1 (de) 1983-12-30 1985-07-11 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Mittel und verfahren zur spezifischen immunologischen bestimmung des c-terminalen parathormonfragments 68-84
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
WO1994003201A1 (en) 1992-08-05 1994-02-17 Hilliker Sandra R Parathyroid hormone fragments and analogs
DE4434551A1 (de) 1994-09-28 1996-04-04 Forssmann Wolf Georg Prof Dr D Peptide aus der Sequenz des hPTH (1-37)
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US6923968B2 (en) 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism

Also Published As

Publication number Publication date
EP1448217A4 (en) 2008-05-14
US20030157560A1 (en) 2003-08-21
JP2005513419A (ja) 2005-05-12
WO2003039572A1 (en) 2003-05-15
US20060223119A1 (en) 2006-10-05
US7056655B2 (en) 2006-06-06
EP1448217A1 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
US7056655B2 (en) Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
Shane et al. Hypercalcemia: pathogenesis, clinical manifestations, differential diagnosis, and management
US8470543B2 (en) Methods for differentiating and monitoring parathyroid and bone status related diseases
JP4231106B2 (ja) 骨溶解および転移を改善する方法
US8298770B2 (en) Methods, kits, and antibodies for detecting parathyroid hormone
Allgrove et al. Hypomagnesaemia: studies of parathyroid hormone secretion and function
US6524788B1 (en) Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
Ranga et al. Growth hormone-releasing factor stimulation test in depression
Emerson et al. Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses
Mitlak et al. Parathyroid hormone-related peptide mediates hypercalcemia in an islet cell tumor of the pancreas
US7541140B2 (en) Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
US7465703B1 (en) Methods and kits useful for guiding osteoporosis related therapy
JP2009511426A (ja) ミネラルおよび骨格代謝の調節
LU100168B1 (en) Prevention of Bone and Mineral Disorders by Restoring Calcium and Phosphate Homeostasis in Patients Suffering from Chronic Kidney Disease
Holt et al. Physiology and pathophysiology of the parathyroid glands and preoperative evaluation
Reddi Disorders of Calcium: Hypercalcemia
US20100021496A1 (en) Methods, kits, and antibodies for quantitative determination of parathyroid hormone molecules with intact c-terminus
Ishimura et al. Effect of aminohydroxypropylidene diphosphonate on the bone metabolism of patients with parathyroid adenoma
Gallacher Use of currently available diagnostic and therapeutic tools in the investigation and treatment of disorders of bone and calcium metabolism
Paterson Hypocalcaemia: differential diagnosis and investigation
Cundy et al. CALCIUM METABOLISM Biological role of calcium
Fiore et al. Cimetidine-induced PTH variations in uraemic patients evaluated with the aid of antisera against the terminal carboxyl and amino groups of the hormone molecule
CN119258199A (zh) 特立帕肽或其盐在骨质疏松症治疗和/或预防剂的制备中的应用
Yates Effects of diphosphonates in disorders of bone turnover.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued